Description |
Levetiracetam is a third-generation antiepileptic drug known in the UK and USA. |
Generic formulation |
MHRA/ CHM advice to minimize risk when switching patients with epilepsy between different manufacturers’ products (including generic products):
- It is usually unnecessary to ensure that patients are maintained on a specific manufacturer’s product unless there are specific concerns, such as patient anxiety and risk of confusion/ dosing error.
|
Indications |
Epilepsy: monotherapy (not approved in USA) and adjunctive therapy of focal seizures with or without secondary generalization.
Recommendations summarized from NICE (2012)
- Seizure types: first line (myoclonic seizures, focal seizures), adjunctive (generalized tonic- clonic seizures, myoclonic seizures, focal seizures), on referral to tertiary care (absence seizures).
- Epilepsy types: first line (juvenile myoclonic epilepsy, benign epilepsy with centrotemporal spikes, Panayiotopoulos syndrome, late-onset childhood occipital epilepsy), adjunctive (juvenile myoclonic epilepsy, epilepsy with generalized tonic- clonic seizures only, idiopathic generalized epilepsy, benign epilepsy with centrotemporal spikes, Panayiotopoulos syndrome, late- onset childhood occipital epilepsy).
|
|
|